1. United Kingdom Stocks

  2. •

    Health technology

  3. •

    Biotechnology
HemoGenyx Pharmaceuticals Plc

HemoGenyx Pharmaceuticals Plc

LLSE:HEMO
696.50
GBX
-28.50
(-3.93%)
3.46BMarket Cap
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-0.04
-2.89
-3.63
-1.72
-1.61
-2.01
-2.64
-1.62
-2.37
-1.7
-2.2
- -
Free Cash Flow per Basic Share
-0.04
-4.48
-0.79
-1.53
-1.34
-1.9
-1.78
-1.36
-2.2
-1.26
-0.78
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.27
2.32
2.37
1.07
-0.38
0.82
3.34
1.34
0.96
0.26
0.2
0.2
Tangible Book Value per Share
0.27
0.64
2.08
0.76
-0.67
0.59
3.16
1.16
0.8
0.12
0.17
0.17
Basic Weighted Avg Shares
- -
- -
1
1
1
1
2
2
3
3
4
5
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
1
1
1
- -
Net Income, GAAP
- -
- -
-2
-2
-1
-2
-5
-4
-7
-6
-10
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Working Capital
- -
- -
2
2
- -
- -
7
2
1
- -
1
1
LT Debt
- -
- -
- -
1
1
- -
- -
3
3
2
2
2
Total Equity
- -
- -
2
1
- -
1
8
3
3
1
1
1
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-218.05
-187.43
-99.92
- -
- -
-112.29
-69.4
-219.58
-302.41
-932.71
- -

Capital Structure

GBP

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
2
2
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
4
5
6
Market Capitalization
14
7
35

Working Capital

GBP

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
1
1
2
Cash, Cash Equivalents & STI
- -
- -
2
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
1
1
1
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

GBP

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
141.75%
144.59%
34.09%
Free Cash Flow
1,182.7%
21.58%
-16.89%
Net Income, GAAP
806.26%
49.75%
73.7%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Semi-annual Earnings Per Share

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-2.37
2024
- -
- -
-1.7
2025
- -
- -
-2.2

Semi-annual Dividends Per Share

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Vladislav Sandler
Full Time Employees
9
Sector
Health technology
Industry
Biotechnology
Address
6 Heddon Street London GL United Kingdom W1B 4BT
IPO Date
Nov 9, 2015
Website
hemogenyx.com
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Hemogenyx Pharmaceuticals Plc is a clinical-stage biotechnology company specializing in the discovery, development, and commercialization of innovative treatments for blood cancers, autoimmune diseases, and viral infections. The company’s core product portfolio includes the HG-CT-1 CAR-T cell therapy for relapsed or refractory acute myeloid leukemia (R/R AML), currently in Phase I clinical trials; the Chimeric Bait Receptor (CBR) platform, which programs immune cells to target viral pathogens; and the CDX bispecific CD3-FLT3 antibody and CAR-T therapies designed for patient conditioning in bone marrow transplantation. Hemogenyx operates primarily in the United Kingdom and the United States, with headquarters in London and US subsidiaries in New York. Founded in 2013 and publicly listed on the London Stock Exchange since 2014, Hemogenyx focuses on innovative cell therapies and immunotherapies within the pharmaceuticals and biotechnology industry. Recent significant developments include the successful initiation of Phase I clinical trials for HG-CT-1 with expansion to include pediatric patients, following FDA clearance; progression of the CBR antiviral/biodefense platform with new patent filings; a collaboration with Kure.ai to develop an ultrafast CAR-T manufacturing process; and multiple funding rounds raising millions of British pounds to support clinical and product development efforts. The company continues to advance its pipeline with strategic clinical site openings, updated trial protocols, and research collaborations to address critical unmet medical needs in hematologic oncology and infectious disease treatment. Hemogenyx Pharmaceuticals has established itself as a clinical-stage biotechnology entity committed to delivering breakthrough therapies for life-threatening blood disorders and related diseases with a focus on innovation, patient impact, and value creation for stakeholders. The company integrates its platform technologies and novel treatment candidates to expand therapeutic opportunities across global markets.